Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Robert D who wrote (5856)	3/10/1998 8:04:00 PM
From: RT	Read Replies (1) \| Respond to of 23519

Robert D, It looks like Dr. Bond may have abandoned ship. He hasn't posted any script data for two weeks nor has he ever told us the essence of the positive news from his sources at Vivus. I suspect he just ran out of good news. If the script data came in weak after spending all those millions on advertising, were really screwed. Today's stock decline, may have been the result of just that. I suspect the impending release of Viagara is also beginning to hurt Muse sales. With all the positive TV coverage that Viagara has received lately, most men will wait a few extra months to try Viagara first, rather than opting for Muse. Think about it. If you were suffering from ED and were told that a pill would be available in a few months, won't you wait to try it first. On the flip side, if it doesn't work and Tunica is your doctor, you ask, what's next, and he says Muse. RT